AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

FESS advocates a systematic approach to the surgical treatment of diseases of the nose and paranasal sinuses. By implementing a systematic approach to nasal endoscopic examination, physicians can ...

Do any of these symptoms sound familiar: Stuff or Runny Nose? Headaches? Sinus Pressure? Snoring? Many of you probably recognize all of them. But, did you realize any attempt to self-medicate will ...

Spring is in full swing and perhaps you’ve found yourself battling nasal congestion. Three common causes are colds, hay fever and sinusitis. Nasal congestion happens when something irritates the ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

Nasal polyps are benign (non-cancerous) growths that develop inside the nose or sinuses. Common causes of nasal polyps include asthma, allergies, and chronic sinus infections. Nasal polyps are ...

Subjective — but not objective — olfactory improvements in patients who underwent endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps were maintained up to 6 months after ...

If nasal congestion persists, pus can accumulate in the sinuses and inflammation can spread If inflammation continues, polyps can also develop in the sinuses I thought, if this continues ...

Both trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52.

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...